Rubric Capital Management (New York)’s Aerie Pharmaceuticals AERI Stock Holding History

Rubric Capital Management (New York)’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,231,483	Closed	-$9.24M	–	97
2022 Q2	$9.24M	Buy	+1,231,483	New	+$8.68M	0.49%	45
2021 Q2	–	Sell	-480,402	Closed	-$8.59M	–	78
2021 Q1	$8.59M	Buy	+480,402	New	+$8.3M	0.5%	50
2019 Q2	–	Sell	-164,070	Closed	-$7.79M	–	74
2019 Q1	$7.79M	Sell	164,070 -398,115	-71%	-$17.5M	0.73%	43
2018 Q4	$20.3M	Buy	+562,185	New	+$26.4M	2.51%	18

Other funds holding AERI

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rubric Capital Management (New York)'s AERI Position: Q3 2022 in Review

Rubric Capital Management (New York) sold out of Aerie Pharmaceuticals (AERI) in Q3 2022, closing a stake of 1,231,483 shares — an estimated $9.24M sold.

Rubric Capital Management (New York) first reported a position in AERI in Q4 2018 and held it in 4 quarters. The position peaked at $20.3M in Q4 2018. 156 funds tracked by Wall St. Rank hold AERI as of Q3 2022.

Rubric Capital Management (New York) reported no remaining Aerie Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Rubric Capital Management (New York) sold 1,231,483 Aerie Pharmaceuticals shares in Q3 2022, an estimated $9.24M.
Rubric Capital Management (New York) first reported a position in Aerie Pharmaceuticals in Q4 2018 and held it in 4 quarters.
Rubric Capital Management (New York)'s Aerie Pharmaceuticals position peaked at $20.3M in Q4 2018.
156 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2022.

Based on Rubric Capital Management (New York)'s 13F filing for Q3 2022, filed 14 Nov 2022.